分子靶向治疗(消化道肿瘤).pptVIP

10例胃癌从首次复发转移至死亡 化疗现状 5FU/顺铂或ECF方案为常规参考方案 泰索帝,奥沙利铂,依立替康,作为备选 化疗使晚期胃癌患者生存延长 4 ~ 6月 阿帕替尼有较好的研究前景 FOLFIRI联合爱必妥有可能成为很好的二线化疗方案 通过多学科联合治疗，辅以分子靶向治疗，有可能在不久的将来获得重大突破。 Thank you! Good afternoon, everyone. Thanks to the oganizer of this joint meeting to provide me an opportunity to give a talk here. The topic of my speech is about the Cetuximab (Erbitux): Cetuximab is an antibody against the EGFR protein, which is present in high amounts on some tumor cells. Bevacizumab (Avastin): Bevacizumab works against the VEGF protein, which normally helps tumors develop new blood vessels in order to get nutrients. These two antibodys are used along with chemotherapy to treat metastatic colorectal cancer. The QoL-data will round up the positive outcome for the EPIC trial . QoL data will be presented at ASCO 2007. The response rate of 4% for irinotecan alone shows exactly the benchmark of the previous phase III studies, mentioned at the beginning. The addition of Erbitux resulted in a 4times higher RR (16%), which is highly significant (p0.0001) and is although reflected in an 15% higher DCR. It is remarkable, that 9 patients had a CR in the combination arm compared to only 1 patient in the irinotecan alone arm. The PFS of 2.5 months for irinotecan alone shows exactly the benchmark in the previous mentioned phase III study. The addition of Erbitux improved the PFS by 54% to 4 month, which again was highly significant and resulted in an impressive hazard ratio of 0.692. Having seen this, one would expect a clear impact on OS said by Alberto Sobrero It makes a big difference if oxaliplatin or irinotecan is administered first line: The efficacy after oxaliplatin failure is very limited with only 4%for RR and 2.5 months for PFS Compared to patients who failed on irinotecan the RR is between 10 - 15% and the PFS is around 5 months. 4% RR and 2.5 months for PFS are the benchmarks for our study. - The European BOND study was a pivotal randomized phase II trial in patients with E